RESUMEN
Cestodes are emerging agents of severe opportunistic infections among immunocompromised patients. We describe the first case of human infection, with the recently-proposed genus Versteria causing an invasive, tumor-like hepatic infection with regional and distant extension in a 53-year-old female kidney transplant recipient from Atlantic Canada.
Asunto(s)
Cestodos/aislamiento & purificación , Infecciones por Cestodos/diagnóstico , Infecciones por Cestodos/patología , Trasplante de Riñón , Parasitosis Hepáticas/diagnóstico , Parasitosis Hepáticas/patología , Receptores de Trasplantes , Animales , Canadá , Femenino , Humanos , Huésped Inmunocomprometido , Persona de Mediana EdadRESUMEN
We investigated an outbreak of surgical site infections that occurred in a tertiary care hospital in Quebec, Canada. This investigation revealed that a change in the sterilization process of the ultrasonic surgical aspirator may have caused this outbreak. It emphasizes the fact that the complex designs of surgical power tools may restrict access to cleaning and sterilization agents. Health care professionals should review manufacturers' assembly/disassembly instructions and sterilization/decontamination procedures before use of such tools.
Asunto(s)
Craneotomía/efectos adversos , Craneotomía/instrumentación , Brotes de Enfermedades , Equipos y Suministros , Esterilización/métodos , Infección de la Herida Quirúrgica/epidemiología , Adulto , Anciano , Humanos , Quebec/epidemiología , Estudios Retrospectivos , Centros de Atención Terciaria , Adulto JovenRESUMEN
BACKGROUND: Clostridium difficile infection (CDI) is associated with a high risk of recurrence (rCDI). Few studies have focused on multiple recurrences. To evaluate the potential of novel treatments targeting recurrence, we assessed the burden and severity of rCDI. METHODS: This was a retrospective cohort of adults diagnosed with CDI in a hospital in Sherbrooke, Canada (1998-2013). An rCDI episode was defined by the reappearance of diarrhea leading to a treatment, with or without a positive toxin assay, within 14-60 days after the previous episode. RESULTS: We included 1527 patients. The probability of developing a first rCDI was 25% (354/1418); a second, 38% (128/334); a third, 29% (35/121); and a fourth or more, 27% (9/33). Two or more rCDIs were observed in 9% (128/1389) of patients. The risk of a first recurrence fluctuated over time, but there was no such variation for second or further recurrences. The proportion of severe cases decreased (47% for initial episodes, 31% for first recurrences, 25% for second, 17% for third), as did the risk of complicated CDI (5.8% to 2.8%). The severity and risk of complications of first recurrences decreased over time, while oral vancomycin was used more systemically. A hospital admission was needed for 34% (148/434) of recurrences. CONCLUSIONS: This study documented the clinical and healthcare burden of rCDI: 34% of patients with rCDI needed admission, 28% developed severe CDI, and 4% developed a complication. Secular changes in the severity of recurrences could reflect variations in the predominant strain, or better management.